Tutto DSpace

Sfoglia per Soggetto "Carcinoma, Hepatocellular"

Items 1-13 di 13

    • aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis 

      Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., Mo S., Sypsa V., Guha I.N., Kumada T., Niu J., Dalekos G., Yasuda S., Barnes E., Lian J., Suri V., Idilman R., Barclay S.T., Dou X., Berg T., Hayes P.C., Flaherty J.F., Zhou Y., Zhang Z., Buti M., Hutchinson S.J., Guo Y., Calleja J.L., Lin L., Zhao L., Chen Y., Janssen H.L.A., Zhu C., Shi L., Tang X., Gaggar A., Wei L., Jia J., Irving W.L., Johnson P.J., Lampertico P., Hou J. (2020)
      Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the ...

    • Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN) 

      Wranke A., Pinheiro Borzacov L.M., Parana R., Lobato C., Hamid S., Ceausu E., Dalekos G.N., Rizzetto M., Turcanu A., Niro G.A., Lubna F., Abbas M., Ingiliz P., Buti M., Ferenci P., Vanwolleghem T., Hayden T., Dashdorj N., Motoc A., Cornberg M., Abbas Z., Yurdaydin C., Manns M.P., Wedemeyer H., Hardtke S., Serrano B., Wöbse M., Heidrich B., Muche M., Gatselis N., Zachou K., Ho E., Smedile A., Fontana R., Gish R., Obretin D., Stern R., the Hepatitis Delta International Network (2018)
      Background & Aims: Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with hepatitis D virus (HDV) infection and treatment approaches in different regions ...

    • Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population 

      Papatheodoridis G.V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., Goulis J., Calleja J.L., Chi H., Manolakopoulos S., Loglio A., Siakavellas S., Gatselis N., Keskın O., Lehretz M., Savvidou S., de la Revilla J., Hansen B.E., Kourikou A., Vlachogiannakos I., Galanis K., Idilman R., Colombo M., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2018)
      Background & Aims: The effects of long-term antiviral therapy on survival have not been adequately assessed in chronic hepatitis B (CHB). In this 10-centre, ongoing cohort study, we evaluated the probability of survival ...

    • The epidemiology, staging and outcomes of sarcomatoid hepatocellular carcinoma: A SEER population analysis 

      Giannis D., Morsy S., Geropoulos G., Esagian S.M., Sioutas G.S., Moris D. (2021)
      Background: Hepatocellular carcinoma (HCC) subtypes differ in terms of histopathology and prognosis. Sarcomatoid HCC is rare and literature concerning the survival of patients with sarcomatoid HCC is scarce. Materials and ...

    • Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece 

      Gatselis N.K., Zachou K., Lygoura V., Azariadis K., Arvaniti P., Spyrou E., Papadamou G., Koukoulis G.K., Dalekos G.N., Rigopoulou E.I. (2017)
      Background & aims Primary biliary cholangitis (PBC) is a disease with rising prevalence and considerable geographical variation. To describe the prevalence, spatial and time distribution, baseline characteristics, response ...

    • Granulin a synergizes with cisplatin to inhibit the growth of human hepatocellular carcinoma 

      Qiao G., Xu H., Li C., Li X., Farooqi A.A., Zhao Y., Liu X., Liu M., Stagos D., Lin X. (2018)
      Cisplatin is one of the most potent chemotherapy drugs widely used for cancer treatment. However, due to resistance and toxicity, the application of cisplatin for the treatment of hepatocellular carcinoma (HCC) is limited. ...

    • Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B 

      Papatheodoridis G.V., Sypsa V., Dalekos G.N., Yurdaydin C., Van Boemmel F., Buti M., Calleja J.L., Chi H., Goulis J., Manolakopoulos S., Loglio A., Voulgaris T., Gatselis N., Keskin O., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Idilman R., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)
      Background & Aims: Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the ...

    • Hepatocyte autotaxin expression promotes liver fibrosis and cancer 

      Kaffe E., Katsifa A., Xylourgidis N., Ninou I., Zannikou M., Harokopos V., Foka P., Dimitriadis A., Evangelou K., Moulas A.N., Georgopoulou U., Gorgoulis V.G., Dalekos G.N., Aidinis V. (2017)
      Autotaxin (ATX) is a secreted lysophospholipase D that catalyzes the production of lysophosphatidic acid (LPA), a pleiotropic growth-factor–like lysophospholipid. Increased ATX expression has been detected in various chronic ...

    • Inhibition of calcitriol inactivating enzyme CYP24A1 gene expression by flavonoids in hepatocellular carcinoma cells under normoxia and hypoxia 

      Angeli-Terzidou A.E., Gkotinakou I.-M., Pazaitou-Panayiotou K., Tsakalof A. (2021)
      A vast number of epidemiological, preclinical and in vitro experimental data strongly indicate the anticancer potential of calcitriol, the biologically active form of vitamin D. However, for the implementation of a vitamin ...

    • PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy 

      Papatheodoridis G., Dalekos G., Sypsa V., Yurdaydin C., Buti M., Goulis J., Calleja J.L., Chi H., Manolakopoulos S., Mangia G., Gatselis N., Keskin O., Savvidou S., De La Revilla J., Hansen B.E., Vlachogiannakos I., Galanis K., Idilman R., Colombo M., Esteban R., Janssen H.L.A., Lampertico P. (2016)
      Background & Aims Risk scores for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This nine center cohort study aimed to develop ...

    • The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B 

      Papatheodoridis G.V., Idilman R., Dalekos G.N., Buti M., Chi H., van Boemmel F., Calleja J.L., Sypsa V., Goulis J., Manolakopoulos S., Loglio A., Siakavellas S., Keskın O., Gatselis N., Hansen B.E., Lehretz M., de la Revilla J., Savvidou S., Kourikou A., Vlachogiannakos I., Galanis K., Yurdaydin C., Berg T., Colombo M., Esteban R., Janssen H.L.A., Lampertico P. (2017)
      Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy with potent nucleos(t)ide analogues is currently unclear. We therefore assessed the HCC incidence ...

    • Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B 

      Papatheodoridis G.V., Dalekos G.N., Idilman R., Sypsa V., Van Boemmel F., Buti M., Calleja J.L., Goulis J., Manolakopoulos S., Loglio A., Papatheodoridi M., Gatselis N., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Yurdaydin C., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)
      Background & Aims: A recent study in Asian patients with chronic hepatitis B (CHB) reported that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with tenofovir disoproxil fumarate (TDF) than ...

    • The state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conference 

      Hatzakis, A.; Van Damme, P.; Alcorn, K.; Gore, C.; Benazzouz, M.; Berkane, S.; Buti, M.; Carballo, M.; Cortes Martins, H.; Deuffic-Burban, S.; Dominguez, A.; Donoghoe, M.; Elzouki, A. N.; Ben-Alaya Bouafif, N.; Esmat, G.; Esteban, R.; Fabri, M.; Fenton, K.; Goldberg, D.; Goulis, I.; Hadjichristodoulou, T.; Hatzigeorgiou, T.; Hamouda, O.; Hasurdjiev, S.; Hughes, S.; Kautz, A.; Malik, M.; Manolakopoulos, S.; Matičič, M.; Papatheodoridis, G.; Peck, R.; Peterle, A.; Potamitis, G.; Prati, D.; Roudot-Thoraval, F.; Reic, T.; Sharara, A.; Shennak, M.; Shiha, G.; Shouval, D.; Sočan, M.; Thomas, H.; Thursz, M.; Tosti, M.; Trépo, C.; Vince, A.; Vounou, E.; Wiessing, L.; Manns, M. (2013)
      The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk ...